Symbols

BNTX

BioNTech·NASDAQ

--(--)

BNTX fundamentals

BNTX Q4 2025 Earnings

BioNTech (BNTX) released its earnings on Mar 10, 2026: revenue was 1.06B (YoY -13.79%), beat estimates; EPS was -0.3862 (YoY -134.54%), missed estimates.

Revenue / YoY

1.06B

-13.79%

EPS / YoY

-0.3862

-134.54%

Report date

Mar 10, 2026

BNTX Earnings Call Summary for Q4,2025

Oncology Pipeline Momentum: 6 late-stage readouts expected in 2026, including Pumitamig Phase III trials and ADC Phase III in prostate cancer.
Strategic Deal Success: BMS partnership strengthens Pumitamig execution, and new mRNA company launched for next-gen innovations.
Financial Strength: EUR 17.2 billion in cash, 2026 guidance for total revenues EUR 2-2.3 billion, and disciplined R&D spending.
Leadership Transition: Ugur and Ozlem remain until end-2026, with search for successors focused on commercial execution.
COVID-19 Vaccine Decline: 2026 revenues expected to drop, but oncology pipeline investments offset the impact.

Earnings

EPS

Revenue

Revenue & Expenses

BNTX has released its 2025 Q3 earnings report, with revenue of 1.78B, reflecting a YoY change of 28.48%, and net profit of -33.68M, showing a YoY change of -115.25%. The Sankey diagram below clearly presents BNTX's revenue sources and cost distribution.

Key Indicators

BioNTech (BNTX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

BioNTech (BNTX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

BioNTech (BNTX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

BioNTech (BNTX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown